ArticleEuropean heart journal2022
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.
Article in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Prognostic value of CMR parametric mapping in cardiac amyloidosis: an updated systematic review and meta-analysis.Open heart · 2025Pooled it
- SCMR expert consensus statement for cardiovascular magnetic resonance of patients with a cardiac implantable electronic device.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2024Guideline
- Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.JACC. Cardiovascular imaging · 2025Trial
- Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis.JACC. Cardiovascular imaging · 2024Trial
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.The New England journal of medicine · 2023Trial
- Automated echocardiographic measurements for longitudinal monitoring of ATTR cardiomyopathy: agreement and repeatability analysis.The international journal of cardiovascular imaging · 2026Article
- Imaging Advances in Light Chain Amyloidosis.Diagnostics (Basel, Switzerland) · 2026Review
- [Cardiovascular magnetic resonance imaging: routine use in cardiology and unique strengths].Innere Medizin (Heidelberg, Germany) · 2026Review
- Prognostic value of echocardiography in light chain cardiac amyloidosis: after adjusting for treatment status.Quantitative imaging in medicine and surgery · 2026Article
- Multimodal Imaging for Monitoring of Disease Progression in Cardiac Amyloidosis: Advances and Gaps in Evidence.Journal of cardiovascular development and disease · 2026Review
- Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging.European heart journal. Cardiovascular Imaging · 2026Review
- Transthyretin amyloid cardiomyopathy: from cause to novel treatments.European heart journal · 2026Review
- Unveiling the unseen: navigating heart involvement in amyloidosis with biomarkers beyond the horizons of imaging.European heart journal. Imaging methods and practice · 2026Review
- Multimodality Imaging in Cardiac Amyloidosis.Journal of clinical medicine · 2025Review
- Monitoring heart involvement in treated and untreated transthyretin amyloidosis.Heart failure reviews · 2025Review
- Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance.European heart journal · 2025Article
- Non-Invasive Diagnostic Algorithm in Transthyretin Cardiac Amyloidosis: Is Bone Scintigraphy Always Enough?Journal of clinical medicine · 2025Review
- Predicting prognosis of light-chain cardiac amyloidosis by magnetic resonance imaging and deep learning.European heart journal. Cardiovascular Imaging · 2025Article
- Progression of QRS duration - a potential surrogate marker of survival in ATTRwt amyloidosis patients.Orphanet journal of rare diseases · 2025Article
- Correlation between the extracellular volume fraction and hemodynamic parameters in light-chain cardiac amyloidosis patients.Quantitative imaging in medicine and surgery · 2025Article
Corrections and comments
- Commented on by
Authors and funding
27 authors at 4 institutions in 2 countries.
Funding
Abstract
aimsTo assess the ability of cardiovascular magnetic resonance (CMR) to (i) measure changes in response to chemotherapy; (ii) assess the correlation between haematological response and changes in extracellular volume (ECV); and (iii) assess the association between changes in ECV and prognosis over and above existing predictors. METHODS AND
resultsIn total, 176 patients with cardiac AL amyloidosis were assessed using serial N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography, free light chains and CMR with T1 and ECV mapping at diagnosis and subsequently 6, 12, and 24 months after starting chemotherapy. Haematological response was graded as complete response (CR), very good partial response (VGPR), partial response (PR), or no response (NR). CMR response was graded by changes in ECV as progression (≥0.05 increase), stable (<0.05 change), or regression (≥0.05 decrease). At 6 months, CMR regression was observed in 3% (all CR/VGPR) and CMR progression in 32% (61% in PR/NR; 39% CR/VGPR). After 1 year, 22% had regression (all CR/VGPR), and 22% had progression (63% in PR/NR; 37% CR/VGPR). At 2 years, 38% had regression (all CR/VGPR), and 14% had progression (80% in PR/NR; 20% CR/VGPR). Thirty-six (25%) patients died during follow-up (40 ± 15 months); CMR response at 6 months predicted death (progression hazard ratio 3.82; 95% confidence interval 1.95-7.49; P < 0.001) and remained prognostic after adjusting for haematological response, NT-proBNP and longitudinal strain (P < 0.01).
conclusionsCardiac amyloid deposits frequently regress following chemotherapy, but only in patients who achieve CR or VGPR. Changes in ECV predict outcome after adjusting for known predictors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.